Response To Ustekinumab Treatment In Patients With Systemic Lupus Erythematosus Is Linked To Suppres

This study was intended to apply biomarker data from this clinical study to ascertain if the modulation of interleukin (IL)‐12, IL‐23, or both were correlated with clinical efficacy. Researchers designed a Phase 2, placebo‐controlled study including a total of 102 individuals with autoantibody-positive systemic lupus erythematosus (SLE) and active disease despite standard‐of‐care therapy. Individuals were assigned randomly in a 3:2 ratio to receive intravenous ustekinumab ~6 mg/kg or placebo at week 0, then subcutaneous injections of 90 mg ustekinumab or placebo every 8 weeks. The findings revealed an important role of IL‐12 blockade in the mechanism of action of ustekinumab in SLE.

​

Source